Evidence map›Paper›PMID 37729084›Full record

ArticleEmerging microbes & infections2023

Prostaglandin E2 contributes to

Maurício T Nascimento, Débora L Viana, Fábio C Peixoto, Sérgio M Arruda, Edgar M Carvalho, Lucas P Carvalho

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Emerging microbes & infections, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Maurício T NascimentoLaboratório de Pesquisas Clínicas, LAPEC, Instituto Gonçalo Moniz - Fiocruz, Salvador, Brazil.ORCID 0000-0002-3791-8048
Débora L VianaLaboratório de Pesquisas Clínicas, LAPEC, Instituto Gonçalo Moniz - Fiocruz, Salvador, Brazil.ORCID 0000-0003-2342-1935
Fábio C PeixotoLaboratório de Pesquisas Clínicas, LAPEC, Instituto Gonçalo Moniz - Fiocruz, Salvador, Brazil.ORCID 0000-0003-3804-8192
Sérgio M ArrudaLaboratório Avançado de Saúde Pública, LASP, Instituto Gonçalo Moniz - Fiocruz, Salvador, Brazil.ORCID 0000-0002-3071-6339
Edgar M CarvalhoLaboratório de Pesquisas Clínicas, LAPEC, Instituto Gonçalo Moniz - Fiocruz, Salvador, Brazil.ORCID 0000-0002-2697-8002
Lucas P CarvalhoLaboratório de Pesquisas Clínicas, LAPEC, Instituto Gonçalo Moniz - Fiocruz, Salvador, Brazil.ORCID 0000-0001-5033-1666
Universidade Federal da Bahia · BRFundação Oswaldo Cruz · BR

Funding

Host and parasite factors promoting disease and treatment failure in Leishmania braziliensis patientsR01AI149456 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI CARVALHO, LUCAS P, SCOTT, PHILLIP · 2020 to 2023
$626k
Parasite polymorphism and host immune response in cutaneous leishmaniasis outcomeR01AI136862 · NIAID · FEDERAL UNIVERSITY OF BAHIA · PI CARVALHO, LUCAS P, SCOTT, PHILLIP · 2018 to 2022
$593k
NIAID NIH HHS R01 AI136862NIAID NIH HHS R01 AI149456
6 · The paper itself

Abstract

Patients with cutaneous leishmaniasis (CL) present an exacerbated inflammatory response associated with tissue damage and ulcer development. In recent years, higher rates of failure to pentavalent antimoniate therapy have been observed, yet the underlying reason remains poorly understood. We hypothesize that the eicosanoid PGE2 favours the establishment of infection by

Indexed as

Leishmania braziliensisLeishmaniasis, CutaneousCyclooxygenase 2DinoprostoneHumansNitrobenzenesSulfonamidesCyclooxygenase 2DinoprostoneN-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamideNitrobenzenesSulfonamidesCutaneous leishmaniasisinflammationL. braziliensisPGE2therapeutic failure

Identifiers

PMID37729084
PMCPMC10540647
OpenAlexW4386897478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.